WA
CYTK icon

Wasatch Advisors’s Cytokinetics CYTK Stock Holding History

Wasatch Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-368,183
Closed -$16.9M – 258
2022
Q4 		$16.9M Sell
368,183
-61,090
-14% -$2.63M 0.11% 145
2022
Q3 		$20.8M Sell
429,273
-46,252
-10% -$2.23M 0.14% 132
2022
Q2 		$18.7M Sell
475,525
-685,320
-59% -$27.6M 0.12% 138
2022
Q1 		$42.7M Sell
1,160,845
-1,022,405
-47% -$36.3M 0.21% 102
2021
Q4 		$99.5M Sell
2,183,250
-464,787
-18% -$17.9M 0.41% 73
2021
Q3 		$94.6M Buy
2,648,037
+53,725
+2% +$1.58M 0.38% 86
2021
Q2 		$51.3M Sell
2,594,312
-15,439
-0.6% -$363K 0.21% 102
2021
Q1 		$60.7M Buy
2,609,751
+54,011
+2% +$1.15M 0.27% 92
2020
Q4 		$53.1M Sell
2,555,740
-488,730
-16% -$8.93M 0.26% 92
2020
Q3 		$65.9M Buy
3,044,470
+181,579
+6% +$4.25M 0.42% 77
2020
Q2 		$67.5M Sell
2,862,891
-137,022
-5% -$2.57M 0.49% 68
2020
Q1 		$35.4M Buy
2,999,913
+406,453
+16% +$5.19M 0.37% 74
2019
Q4 		$27.5M Buy
2,593,460
+131,934
+5% +$1.36M 0.23% 97
2019
Q3 		$28M Sell
2,461,526
-755,346
-23% -$9.48M 0.27% 87
2019
Q2 		$36.2M Buy
3,216,872
+28,385
+0.9% +$274K 0.35% 74
2019
Q1 		$25.8M Buy
3,188,487
+731,682
+30% +$5.38M 0.28% 78
2018
Q4 		$15.5M Buy
2,456,805
+564,213
+30% +$4.14M 0.21% 87
2018
Q3 		$18.6M Buy
1,892,592
+62,543
+3% +$502K 0.21% 88
2018
Q2 		$15.2M Buy
1,830,049
+68,167
+4% +$567K 0.18% 95
2018
Q1 		$12.7M Buy
1,761,882
+82,104
+5% +$704K 0.16% 97
2017
Q4 		$13.7M Buy
1,679,778
+977,106
+139% +$11.1M 0.18% 101
2017
Q3 		$10.2M Sell
702,672
-66,518
-9% -$909K 0.14% 113
2017
Q2 		$9.31M Sell
769,190
-723,508
-48% -$10.1M 0.13% 118
2017
Q1 		$19.2M Sell
1,492,698
-178,917
-11% -$2.09M 0.28% 77
2016
Q4 		$20.3M Sell
1,671,615
-51,545
-3% -$547K 0.31% 74
2016
Q3 		$15.8M Sell
1,723,160
-22,936
-1% -$239K 0.24% 98
2016
Q2 		$16.6M Buy
1,746,096
+1,266,854
+264% +$10.4M 0.25% 96
2016
Q1 		$3.23M Buy
479,242
+352
+0.1% +$2.57K 0.05% 229
2015
Q4 		$5.01M Sell
478,890
-68,889
-13% -$676K 0.07% 213
2015
Q3 		$3.67M Hold
547,779
– – 0.05% 246
2015
Q2 		$3.68M Sell
547,779
-1,251
-0.2% -$8.2K 0.04% 269
2015
Q1 		$3.72M Sell
549,030
-72,134
-12% -$539K 0.04% 260
2014
Q4 		$4.98M Sell
621,164
-33,917
-5% -$146K 0.05% 240
2014
Q3 		$2.31M Buy
655,081
+481,905
+278% +$2.02M 0.02% 305
2014
Q2 		$828K Buy
173,176
+24,304
+16% +$148K 0.01% 372
2014
Q1 		$1.41M Sell
148,872
-104,331
-41% -$944K 0.01% 349
2013
Q4 		$1.65M Buy
253,203
+102,787
+68% +$675K 0.02% 323
2013
Q3 		$1.14M Buy
+150,416
New +$1.61M 0.01% 339

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Wasatch Advisors's CYTK Position: Q1 2023 in Review

Wasatch Advisors sold out of Cytokinetics (CYTK) in Q1 2023, closing a stake of 368,183 shares — an estimated $16.9M sold.

Wasatch Advisors first reported a position in CYTK in Q3 2013 and held it in 38 quarters. The position peaked at $99.5M in Q4 2021. 262 funds tracked by Wall St. Rank hold CYTK as of Q1 2023.

  • Wasatch Advisors reported no remaining Cytokinetics position as of Q1 2023 after selling out during the quarter.
  • Wasatch Advisors sold 368,183 Cytokinetics shares in Q1 2023, an estimated $16.9M.
  • Wasatch Advisors first reported a position in Cytokinetics in Q3 2013 and held it in 38 quarters.
  • Wasatch Advisors's Cytokinetics position peaked at $99.5M in Q4 2021.
  • 262 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2023.

Based on Wasatch Advisors's 13F filing for Q1 2023, filed 12 May 2023.